EDSA Insider Trading
Insider Ownership Percentage: 22.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Edesa Biotech Share Price & Price History
Current Price: $1.69
Price Change: ▼ Price Decrease of -0.0328 (-1.90%)
As of 12/4/2025 04:57 PM ET
Edesa Biotech Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/25/2024 | Pardeep Nijhawan | CEO | Buy | 5,000 | $4.00 | $20,000.00 | 341,702 |  |
| 1/9/2023 | Der Velden Peter Van | Major Shareholder | Sell | 20,732 | $18.62 | $386,029.84 | 23,310 | |
Edesa Biotech Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/17/2025 | Susquehanna International Group LLP | 14,610 | $36K | 0.0% | N/A | 0.208% |  |
| 11/17/2025 | Citadel Advisors LLC | 14,032 | $34K | 0.0% | -40.3% | 0.199% | |
| 5/15/2025 | Nantahala Capital Management LLC | 625,000 | $1.53M | 0.1% | N/A | 8.899% | |
| 5/15/2025 | Velan Capital Investment Management LP | 687,500 | $1.68M | 1.7% | N/A | 9.789% | |
| 5/14/2025 | Stonepine Capital Management LLC | 687,500 | $1.68M | 1.6% | N/A | 9.789% | |
| 2/17/2025 | Citadel Advisors LLC | 40,944 | $70K | 0.0% | N/A | 1.180% | |
| 2/14/2025 | Two Sigma Securities LLC | 15,313 | $26K | 0.0% | N/A | 0.441% | |
| 8/2/2024 | CM Management LLC | 90,000 | $0.39M | 0.3% | +45.2% | 2.795% | |
| 11/7/2023 | CM Management LLC | 417,602 | $0.26M | 0.3% | +11.4% | 13.874% | |
| 8/4/2023 | CM Management LLC | 375,000 | $0.30M | 0.3% | +15.4% | 1.821% | |
| 5/8/2023 | CM Management LLC | 325,000 | $0.30M | 0.4% | +3.9% | 1.620% | |
| 2/14/2023 | Susquehanna International Group LLP | 15,211 | $33K | 0.0% | N/A | 0.079% | |
| 2/9/2023 | CM Management LLC | 312,773 | $0.68M | 0.8% | +25.1% | 1.616% | |
| 2/7/2023 | Lynwood Capital Management Inc. | 121,845 | $0.26M | 0.3% | N/A | 0.630% | |
| 11/4/2022 | CM Management LLC | 250,000 | $0.23M | 0.3% | N/A | 1.617% | |
| 8/8/2022 | Merit Financial Group LLC | 20,409 | $33K | 0.0% | N/A | 0.132% | |
| 5/5/2022 | National Bank of Canada FI | 10,000 | $30K | 0.0% | +1,518.1% | 0.072% | |
| 11/16/2021 | Verition Fund Management LLC | 13,502 | $100K | 0.0% | N/A | 0.102% | |
| 10/28/2021 | 180 Wealth Advisors LLC | 20,000 | $0.16M | 0.0% | +33.3% | 0.151% | |
Data available starting January 2016
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Read More on Edesa Biotech
Volume
31,382 shs
Average Volume
29,326 shs
Market Capitalization
$11.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.08
Who are the company insiders with the largest holdings of Edesa Biotech?
Who are the major institutional investors of Edesa Biotech?
Which institutional investors are selling Edesa Biotech stock?
During the previous quarter, EDSA stock was sold by these institutional investors:
- Citadel Advisors LLC
Which institutional investors are buying Edesa Biotech stock?
Within the last quarter, EDSA stock was purchased by institutional investors including:
- Susquehanna International Group LLP
